t
Tissue Regenix Group plc announced on 10 February 2022 additional disclosures under Schedule 2(g) of the AIM Rules for Companies, supplementing details from 5 January 2021. These relate to Non-Executive Director Brian Phillips's past directorships where companies experienced insolvency events. Specifically, a receiver was appointed for Diamond Group Holdings Public Limited Company in 1992 and Alma Holdings Limited in February 1992, administration orders were made for The Allen Partnership Limited and Public House Holdings Limited in October 1992, and Cannock Group Limited entered voluntary creditors' liquidation in December 1998, all while Mr. Phillips was a director.
| Date | 10 Feb 2022 |
| Time | 15:45:01 |
| Category | Miscellaneous |
| ID | 3465B |
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Additional Director Disclosures
Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces the following additional disclosures under Schedule 2(g) of the AIM Rules for Companies relating to Brian Phillips, Non-Executive Director. These are in addition to those details already announced on 5 January 2021.
Mr Phillips' career in private equity resulted in him holding a number of non-executive directorship positions in respect of his firm's investee companies, including the following: Diamond Group Holdings Public Limited Company to which a receiver was appointed in 1992; Mr Phillips was a director of group companies, The Allen Partnership Limited and Public House Holdings Limited, when an administration order was made on both companies in October 1992; Cannock Group Limited went into voluntary creditors' liquidation in December 1998 while Mr Phillips was a director; and a receiver was appointed in respect of the administration of Alma Holdings Limited in February 1992 while Mr Phillips was a director.
For more information:
|
Tissue Regenix Group plc David Cocke, Chief Financial Officer |
Via Walbrook PR |
|
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Alex Price |
Tel: +44(0)20 7710 7600 |
|
Walbrook PR Ltd Alice Woodings / Lianne Applegarth |
Tel: +44 (0)20 7933 8780 |
|
|
|
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.